Fig. 3

Progression-free and overall survival analysis in MM patients based on the peripheral blood plasma concentrations of FGF-2 and VEGF. The hierarchical clustering analysis of MM patients shows three distinct risk groups of patients based on the concentrations of FGF-2 and VEGF. High risk: patients who present both high FGF-2 and VEGF plasma levels showing a worse prognosis with significantly shorter PFS and OS; intermediate risk: patients who present high plasma levels in only one of the two cytokines; low risk: patients who show low blood levels in both angiogenic cytokines. Again, no evident differences between the two therapy regimens were detected